Molecularly defined adult granulosa cell tumor of the ovary: The clinical phenotype

Journal of the National Cancer Institute

Volumn 108, Issue 11, 2016, Pages

  McConechy, Melissa K ^a,j   Farkkila, Anniina ^b,c   Horlings, Hugo M ^a,h   Talhouk, Aline ^a,b   Unkila Kallio, Leila ^c   Van Meurs, Hannah S ^a   Winnie, Yang ^a,e   Rozenberg, Nirit ^a,e   Andersson, Noora ^e   Zaby, Katharina ^f   Bryk, Saara ^f   Butzow, Ralf ^f   Halfwerk, Johannes B G ^f   Hooijer, Gerrit K J ^b   Van De Vijver, Marc J ^b   Buist, Marrije R ^g   Kenter, Gemma G ^e   Brucker, Sara Y ^d   Kramer, Bernhard ^d   Staebler, Annette ^f   Bleeker, Maaike C G ^d   Heikinheimo, Markku ^c   Kommoss, Stefan ^c   Gilks, C Blake ^a,c   Anttonen, Mikko ^b,c   Huntsman, David G ^a,i   more..

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d Centre of Gynaecologic Oncology Amsterdam   (Finland)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^g Department of Pathology ^*  (Germany)

^h ST LOUIS CHILDREN S HOSPITAL   (United States)

ⁱ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^j RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FORKHEAD TRANSCRIPTION FACTOR; FORKHEAD TRANSCRIPTION FACTOR FOXL2; UNCLASSIFIED DRUG; FOXL2 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL OUTCOME; COHORT ANALYSIS; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DISEASE SPECIFIC SURVIVAL; EUROPEAN; FEMALE; FOLLOW UP; GRANULOSA CELL TUMOR; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; MIDDLE AGED; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY; OVARY TUMOR; OVERALL SURVIVAL; PHENOTYPE; POINT MUTATION; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROTEIN FUNCTION; RECURRENCE FREE SURVIVAL; SALPINGOOOPHORECTOMY; SURVIVAL RATE; AGED; CARCINOMA; CLINICAL TRIAL; DNA MUTATIONAL ANALYSIS; FINLAND; GENETICS; GERMANY; MORTALITY; NETHERLANDS; OVARIAN NEOPLASMS; RETROSPECTIVE STUDY; TUMOR RECURRENCE;

ADULT; AGED; CARCINOMA; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC ERRORS; DNA MUTATIONAL ANALYSIS; FEMALE; FINLAND; FORKHEAD TRANSCRIPTION FACTORS; GERMANY; GRANULOSA CELL TUMOR; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NETHERLANDS; OVARIAN NEOPLASMS; PHENOTYPE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 85014838130     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djw134     Document Type: Article

References (29)

1. van Meurs HS, Bleeker MC, van der Velden J, et al. The incidence of endometrial hyperplasia and cancer in 1031 patients with a granulosa cell tumor of the ovary: long-term follow-up in a population-based cohort study. Int J Gynecol Cancer. 2013; 23(8): 1417-1422.
2. Unkila-Kallio L, Leminen A, Tiitinen A, et al. Nationwide data on falling incidence of ovarian granulosa cell tumours concomitant with increasing use of ovulation inducers. Hum Reprod. 1998; 13(10): 2828-2830.
3. Malmstrom H, Hogberg T, Risberg B, et al. Granulosa cell tumors of the ovary: prognostic factors and outcome. Gynecol Oncol. 1994; 52(1): 50-55.
4. Haroon S, Zia A, Idrees R, et al. Clinicopathological spectrum of ovarian sex cord-stromal tumors; 20 years' retrospective study in a developing country. J Ovarian Res. 2013; 6(1): 87.
5. Abu-Rustum NR, Restivo A, Ivy J, et al. Retroperitoneal nodal metastasis in primary and recurrent granulosa cell tumors of the ovary. Gynecol Oncol. 2006; 103(1): 31-34.
6. Rosario R, Wilson M, Cheng WT, et al. Adult granulosa cell tumours (GCT): clinicopathological outcomes including FOXL2 mutational status and expression. Gynecol Oncol. 2013; 131(2): 325-329.
7. Cronje HS, Niemand I, Bam RH, et al. Review of the granulosa-theca cell tumors from the emil Novak ovarian tumor registry. Am J Obstet Gynecol. 1999; 180(2 Pt 1): 323-327.
8. Miller BE, Barron BA, Wan JY, et al. Prognostic factors in adult granulosa cell tumor of the ovary. Cancer. 1997; 79(10): 1951-1955.
9. Shah SP, Kobel M, Senz J, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med. 2009; 360(26): 2719-2729.
10. Schrader KA, Gorbatcheva B, Senz J, et al. The specificity of the FOXL2 c. 402C>G somatic mutation: a survey of solid tumors. PLoS One. 2009; 4(11): e7988.
11. Al-Agha OM, Huwait HF, Chow C, et al. FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary. Am J Surg Pathol. 2011; 35(4): 484-494.
12. Gershon R, Aviel-Ronen S, Korach J, et al. FOXL2 C402G mutation detection using MALDI-TOF-MS in DNA extracted from Israeli granulosa cell tumors. Gynecol Oncol. 2011; 122(3): 580-584.
13. Hes O, Vanecek T, Petersson F, et al. Mutational analysis (c. 402C>G) of the FOXL2 gene and immunohistochemical expression of the FOXL2 protein in testicular adult type granulosa cell tumors and incompletely differentiated sex cord stromal tumors. Appl Immunohistochem Mol Morphol. 2011; 19(4): 347-351.
14. Jamieson S, Butzow R, Andersson N, et al. The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary. Mod Pathol. 2010; 23(11): 1477-1485.
15. Kim MS, Hur SY, Yoo NJ, et al. Mutational analysis of FOXL2 codon 134 in granulosa cell tumour of ovary and other human cancers. J Pathol. 2010; 221(2): 147-152.
16. Kommoss S, Anglesio MS, Mackenzie R, et al. FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines. Mod Pathol. 2013; 26(6): 860-867.
17. McCluggage WG, Singh N, Kommoss S, et al. Ovarian Cellular Fibromas Lack FOXL2 Mutations: A Useful Diagnostic Adjunct in the Distinction From Diffuse Adult Granulosa Cell Tumor. Am J Surg Pathol. 2013; 37(9): 1450-1455.
18. Stewart CJ, Alexiadis M, Crook ML, et al. An immunohistochemical and molecular analysis of problematic and unclassified ovarian sex cord-stromal tumors. Hum Pathol. 2013; 44(12): 2774-2781.
19. Bryk S, Farkkila A, Butzow R, et al. Clinical characteristics and survival of patients with an adult-type ovarian granulosa cell tumor: a 56-year singlecenter experience. Int J Gynecol Cancer. 2015; 25(1): 33-41.
20. van Meurs HS, Schuit E, Horlings HM, et al. Development and internal validation of a prognostic model to predict recurrence free survival in patients with adult granulosa cell tumors of the ovary. Gynecol Oncol. 2014; 134(3): 498-504.
21. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer; 2000.
22. D'Angelo E, Mozos A, Nakayama D, et al. Prognostic significance of FOXL2 mutation and mRNA expression in adult and juvenile granulosa cell tumors of the ovary. Mod Pathol. 2011; 24(10): 1360-1367.
23. Rosario R, Wilson M, Cheng W-T, et al. Adult granulosa cell tumours (GCT): Clinicopathological outcomes including FOXL2 mutational status and expression. Gynecol Oncol. 2013; 131(2): 325-329.
24. Kommoss S, Gilks CB, Penzel R, et al. A current perspective on the pathological assessment of FOXL2 in adult-type granulosa cell tumours of the ovary. Histopathology. 2014; 64(3): 380-388.
25. Maillet D, Goulvent T, Rimokh R, et al. Impact of a second opinion using expression and molecular analysis of FOXL2 for sex cord-stromal tumors. A study of the GINECO group & the TMRO network. Gynecol Oncol. 2014; 132(1): 181-187.
26. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines) Version 3. 2014; Malignant Sex Cord-Stromal tumors, 2014. http: //www. nccn. org. Accessed May 2014.
27. Salani R, Backes FJ, Fung MF, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol. 2011; 204(6): 466-478.
28. Colombo N, Peiretti M, Garbi A, et al. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012; 23(Suppl 7): vii20-vii26.
29. De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol. 2014; 15(1): 23-34.